Alembic Pharmaceuticals has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its API-III manufacturing facility located in Karakhadi, Gujarat. The inspection was conducted between March 17 and March 21, 2025.
The successful completion of the USFDA inspection and receipt of the EIR marks a significant regulatory milestone for Alembic, reinforcing the company’s compliance with global quality standards. The API-III facility plays a key role in the production of active pharmaceutical ingredients (APIs) for Alembic’s global markets.
This development is expected to strengthen Alembic’s position in the US market and support its ongoing growth in international formulations and API exports.
In the meantime, Alembic Pharmaceuticals shares opened at ₹969.00 on Wednesday, and, at the time of writing, reached a high of ₹974.20 and a low of ₹953.10 during intraday trading. The stock remains significantly below its 52-week high of ₹1,303.90 but well above the 52-week low of ₹725.20.
